Visceral leishmaniasis (VL) is an uncommon but potentially fatal complication for solid organ transplant (SOT) recipients ([@R1]*,*[@R2]). Beginning in July 2009, an outbreak of leishmaniasis affected the southwest area of Madrid ([@R3]). The outbreak was primarily located in Fuenlabrada, which has an annual VL incidence of 21.1 cases/100,000 population ([@R4]), notably higher than that estimated for the general population in Spain (0.5 cases/100,000 population) ([@R5]).

Spatial analysis revealed that the highest concentration of cases was in the residential area bordering the park (Bosque Sur) ([@R6]). A large population of *Lepus granatensis* hares, which serve as a reservoir for *Leishmania infantum*, was present in the area ([@R7]*,*[@R8]), and the *Phlebotomus perniciosus* sand fly in Spain can act as a vector and take blood meals from these hares ([@R6],[@R8],[@R9]). Thus, the parkland facilitated the transmission of the leishmaniasis pathogen, which led to the outbreak. This large, urban outbreak provided us the opportunity to analyze the incidence and specific risk factors of VL among SOT recipients.

The Study
=========

The University Hospital 12 de Octubre in Madrid, Spain, acts as the reference hospital for SOT in South Madrid. We performed a retrospective study of all consecutive adult patients who underwent kidney, liver, or heart transplantation during January 1, 2005--January 1, 2013, and lived in the outbreak area. Patients who underwent SOT before January 1, 2005, were excluded because of the difficulty of ensuing long-term follow-up and the potential of heterogeneity in posttransplant practices. Patients who died or had moved to a different place of residence before outbreak onset were excluded ([Technical Appendix](#SD1){ref-type="local-data"} Figure 1).

The primary study outcome was the occurrence of VL, the diagnosis of which required confirmation of parasitemia (online Technical Appendix) ([@R10]). We recorded pretransplant, peritransplant and posttransplant variables and collected various environmental factors prospectively by unblinded, direct interview with the patients. Patients were considered to have frequent contact with dogs if patients reported having dogs at home or taking care of dogs and to have the habit of visiting the park if they reported visiting once a year. The distance between the place of residence and the park was obtained by locating the patient's home address and measuring the shortest linear distance to the nearest border of the parkland by means of an online mapping tool (Google Maps; Google Inc., Mountain View, CA, USA).

The beginning of the exposure period was set as July 2009 (outbreak onset) for patients who underwent SOT before the outbreak and as the transplant date for those who underwent SOT after outbreak onset. In both cases, the exposure period extended to the date of diagnosis of VL, death, or December 2013. We chose to end the study in December 2013 because the incidence of leishmaniasis decreased thereafter because of the implementation of control measures. The clinical research ethics committee of the University Hospital 12 de Octubre approved the study, and participants provided informed consent.

We analyzed 68 patients ([Table 1](#T1){ref-type="table"}) for a median follow-up of 4.4 (interquartile range 2.39--6.95) years. VL was diagnosed in 7 patients, yielding a cumulative incidence of 10.3% (95% CI 3.1%--17.5%) and an annual incidence of 2,997 (95% CI 1,213--6,161) cases per 100,000 population. Details on disease pathology and therapy were recorded ([Table 2](#T2){ref-type="table"}). The mean interval between transplant and diagnosis was 1.34 ± 0.89 years. No patients had visited highly VL-endemic countries.

###### Baseline and clinical characteristics of solid organ transplant recipients in study of risk factors for VL, Madrid, Spain, January 1, 2005--January 1, 2013\*

  Characteristics                                              Overall cohort,  n = 68   VL, n = 7          No VL, n = 61        p value†
  ------------------------------------------------------------ ------------------------- ------------------ -------------------- -----------
  Recipient age, y, mean ± SD                                  51.1 ± 14.2               53.0 ± 15.5        51.0 ± 13.5          0.721
  Male sex, no. (%)                                            48 (70.6)                 6 (85.7)           42 (68.9)            0.664
  Race, no. (%)                                                                                                                  
  White                                                        62 (91.2)                 5 (71.4)           57 (93.4)            0.112
  Black, sub-Saharan African                                   4 (5.9)                   2 (28.6)‡          2 (3.3)              **0.049**
  Other                                                        2 (2.9)                   0 (0)              2 (3.3)              1.000
  Type of SOT, no. (%)                                                                                                           
  Kidney                                                       57 (83.8)                 6 (85.7)           51 (83.6)            1.000
  Liver                                                        8 (11.8)                  0 (0)              8 (13.1)             0.587
  Heart                                                        3 (4.4)                   1 (14.3)           2 (3.3)              0.282
  Donor age, y, mean ± SD                                      46.1 ± 16.2               49.4 ± 17.4        46.3 ± 16.3          0.596
  Cold ischemia time, min, median (IQR)                        1,005 (630--1,354)        795 (371--1,365)   1,020 (660--1,360)   0.370
  No. HLA mismatches, mean ± SD                                4.0 ± 1.2                 5.0 ± 1.0          4.0 ± 1.2            0.265
  DCD donor, no. (%)                                           18 (26.5)                 3 (42.8)           15 (24.6)            0.370
  Transplant during the outbreak, no. (%)                      41 (60.3)                 7 (100.0)          34 (55.7)            **0.037**
  Induction therapy, no. (%)                                                                                                     
  Basiliximab                                                  22 (32.4)                 0 (0)              22 (36.1)            0.087
  Antithymocyte globulin                                       24 (35.3)                 4 (57.1)           20 (32.8)            0.233
  None                                                         22 (32.4)                 3 (42.8)           19 (31.1)            0.673
  Maintenance immunosuppression, no. (%)                                                                                         
  Steroids                                                     56 (82.4)                 7 (100.0)          49 (80.3)            0.338
  Calcineurin inhibitors                                       60 (88.2)                 6 (85.7)           54 (88.5)            1.000
  Mycophenolate mofetil/mycophenolic acid                      47 (61.8)                 4 (57.1)           43 (70.5)            0.668
  mTOR inhibitors                                              10 (14.7)                 1 (14.3)           9 (14.8)             1.000
  Complications in the first year after SOT, no. (%)                                                                             
  Acute graft rejection                                        19 (27.9)                 2 (28.6)           17 (27.9)            1.000
  CMV infection                                                21 (30.9)                 4 (57.1)           17 (27.9)            0.189
  Bacterial infection                                          60 (88.2)                 6 (85.7)           54 (88.5)            0.190
  Environmental factors                                                                                                          
  Frequent contact with dogs, no. (%)                          26 (38.2)                 3 (42.8)           23 (37.7)            1.000
  Habit of visiting the park, no. (%)§                         19 (31.7)                 3 (50.0)           16 (29.6)            0.369
  Distance from patient's residence to park, m, median (IQR)   1,220 (849--1,865)        399 (261--985)     1,370 (974--1,880)   **0.001**

\*CMV, cytomegalovirus; DCD, donation after circulatory death; HLA, human leukocyte antigen; IQR, interquartile range; mTOR, mammalian target of rapamycin; SOT, solid organ transplant; VL, visceral leishmaniasis. †The p values refer to the comparison between patients with and without visceral leishmaniasis. Significant values are in bold. ‡The country of birth of both patients with posttransplant VL was Equatorial Guinea. §Data available for 60 patients.

###### Disease characteristics, demographics, clinical characteristics, therapy, and outcomes of 7 solid organ transplant recipients with VL, Madrid, Spain, January 1, 2005--January 1, 2013\*

  Characteristics                                        Patient no.                                                                         
  ------------------------------------------------------ --------------- ------------- ------------- ------------ ------------- ------------ -------------
  Sex                                                    M               M             M             M            M             F            M
  Race                                                   Black           Black         White         White        White         White        White
  Linear distance from patient's residence to park, m    794             399           261           1,240        985           233          358
  Age at transplant, y                                   35              34            76            55           68            49           52
  Type of SOT                                            Kidney          Kidney        Kidney        Kidney       Kidney        Heart        Kidney
  Donor *Leishmania* spp. serostatus                     Negative        NP            Negative      NP           Negative      Negative     Negative
  Pretransplant recipient *Leishmania* spp. serostatus   NP              NP            Negative      Positive     Negative      Negative     Negative
  Date of transplant                                     2011 Feb 11     2010 Jan 22   2010 Mar 10   2010 Jul 7   2009 Dec 29   2010 Sep 5   2010 Apr 15
  Interval from transplant to VL diagnosis, y            1.17            2.44          0.25          1.4          0.17          1.81         2.21
  Fever at admission                                     Yes             Yes           No            Yes          Yes           Yes          Yes
  Pancytopenia                                           Yes             Yes           Yes           Yes          Yes           Yes          Yes
  Splenomegaly                                           Yes             Yes           Yes           Yes          Yes           Yes          Yes
  Serologic testing results for *Leishmania* spp.        Positive        Negative      Negative      Positive     Negative      Positive     Negative
  Presence of amastigote forms in bone marrow sample     Positive        Positive      Positive      Positive     Positive      Positive     Positive
  PCR assay results of bone marrow sample                NP              NP            NP            Negative     NP            NP           NP
  NNN culture results of bone marrow sample              Positive        NP            Positive      Negative     Negative      Positive     Negative
  Initial therapy                                        L-AmB           L-AmB         L-AmB         L-AmB        L-AmB         L-AmB        L-AmB
  Relapse                                                Yes             No            Yes           Yes          No            No           No
  Outcome                                                Renal failure   Graft loss    Cured         Graft loss   Cured         Cured        Cured

\*L-AmB, liposomal amphotericin B; NNN, Novy-McNeal-Nicolle; NP, not performed; SOT, solid organ transplant; VL, visceral leishmaniasis.

Black sub-Saharan African SOT recipients were more likely than other recipients to become affected by VL (relative risk 6.40, 95% CI 1.76--23.29, p = 0.049) ([Table 1](#T1){ref-type="table"}). All 7 episodes of VL occurred in patients who underwent transplantation during the outbreak period ([Figure 1](#F1){ref-type="fig"}).

![Distribution of VL among solid organ transplant recipients, Madrid, Spain, January 1, 2005--January 1, 2013. Columns represent the number of solid organ transplant procedures performed each year at the University Hospital 12 de Octubre among patients permanently residing in Fuenlabrada, the nearby city affected by the outbreak. Gray shading indicates outbreak period. SOT, solid organ transplant; VL, visceral leishmaniasis.](15-1251-F1){#F1}

The median distance between the place of residence and the park was significantly shorter for recipients with VL (399 m) than for those without (1,370 m; p = 0.001) ([Figure 2](#F2){ref-type="fig"}; [Technical Appendix](#SD1){ref-type="local-data"} Figure 2). We explored the predictive accuracy of this variable by establishing the optimal cutoff value with the area under the receiving operating characteristic curve analysis. Recipients living \<1,000 m from the park (26.1%, 6/23) had a higher incidence of VL than recipients living [\>]{.ul}1,000 m away (2.2%, 1/45; relative risk, 11.74, 95% CI 1.50--91.78; p = 0.005). At 4 years, a lower percentage of the SOT recipients living \<1,000 m from the park were free from VL than those living [\>]{.ul}1,000 m away (61.0% vs 98%; p = 0.001 by log-rank test) ([Technical Appendix](#SD1){ref-type="local-data"} Figure 3).

![Spatial distribution of solid organ transplant recipients in the southwest area of Madrid, Spain, in relation to park that was focus of visceral leishmaniasis (VL) outbreak, January 1, 2005--January 1, 2013. Map inset shows the location of the outbreak in relation to the rest of Spain. VL, visceral leishmaniasis.](15-1251-F2){#F2}

Our study suggests that the incidence of VL in SOT recipients is notably higher than that in the general population ([@R11]). Acquisition of the parasite most likely occurred posttransplant because all but 1 recipient affected with VL (from whom serum samples could be recovered) were seronegative for *Leishmania* spp. before transplantation.

Our findings suggest that environmental factors might be crucial in modulating the incidence of VL in immunocompromised hosts, such as SOT recipients; the distance from the patient's residence to the focus of the outbreak ([@R6]*,*[@R7]) emerged as a key risk factor. The median distance between the park and the homes of recipients with posttransplant VL was \<500 m; the maximum flight distance of female sand flies is 600 m ([@R12]*,*[@R13]). Therefore, persons living within this radius had a higher chance of being bitten by the VL vector. A similar association was described for the general population during this outbreak ([@R6]).

Undergoing transplantation during the outbreak period was another risk factor for VL. This finding suggests that, in the case of an outbreak in a country with low baseline incidence, pretransplant screening of patients listed for SOT for VL-specific antibodies should be considered and repeated during the posttransplant period for the prompt detection of de novo infection. Recipients should also receive specific counseling to reduce the risk of being bitten by sand flies. In addition, treating physicians must maintain a low threshold of suspicion for VL for persons on immunosuppressive therapy during a VL outbreak.

We found that 28% of posttransplant VL cases occurred in black recipients born in sub-Saharan Africa, even though this subgroup only represented 2.4% of the overall population in the affected area ([@R14]). An association between sub-Saharan African ethnicity and VL has also been reported in the general population ([@R4]). No apparent relationship was found between the race of the patient and the frequency of parkland visits. Both black recipients in question came from Equatorial Guinea, a country not considered endemic for leishmaniasis by the World Health Organization ([@R15]). Therefore, the potential association between genetic susceptibility and posttransplant VL warrants further investigation.

Limitations of this study include the small sample size and that interviewers were not blinded to the diagnosis of VL. However, the objective nature of the questionnaire minimized the potential risk for bias. When assessing degree of exposure to sand flies, we used only indirect variables (i.e., distance between the patient's residence and park, habit of visiting the park) as surrogate measures. Regarding the distance from the park, only linear distances were assessed without considering the potential presence of physical obstacles in the sand fly flight trajectory. Because of these limitations, our findings must be interpreted with caution.

Conclusions
===========

Our study indicates several risk factors (being black and from sub-Saharan Africa, having an SOT during the outbreak, and living \<1,000 m from the outbreak focus) useful for helping physicians treat SOT recipients during a VL outbreak. Doctors should select the patients with these risk factors for counseling to minimize their exposure to vectors and active monitoring for prompt diagnosis.

###### Technical Appendix

Methods used to confirm visceral leishmaniasis (VL) diagnosis, flow chart of solid organ transplant (SOT) recipients included in the study, box-whisker plot comparing linear distances from outbreak focus area (park) to residences of the SOT recipients with and without VL, and Kaplan-Meier curve analysis showing differences in VL disease onset in SOT recipients on the basis of distance from park.
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